UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.618

Sortiert nach

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines

Journal of experimental & clinical cancer research, 2017-12, Vol.36 (1), Article 174

2017

Volltextzugriff (PDF)

Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines

Biochemical pharmacology, 2024-03, p.116161-116161, Article 116161

2024

Volltextzugriff (PDF)

Inorganic sulfides prevent osimertinib-induced mitochondrial dysfunction in human iPS cell-derived cardiomyocytes

Journal of pharmacological sciences, 2024-10, Vol.156 (2), p.69-76

2024

Volltextzugriff (PDF)

Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations

Journal of thoracic oncology, 2021-05, Vol.16 (5), p.764-773

2021

Volltextzugriff (PDF)

Strategies for enhancing non-small cell lung cancer treatment: Integrating Chinese herbal medicines with epidermal growth factor receptor-tyrosine kinase inhibitors therapy

European journal of pharmacology, 2024-10, Vol.980, p.176871, Article 176871

2024

Volltextzugriff (PDF)

Gefitinib Resensitization After a TKI-Free Interval in Osimertinib Resistant Non–Small-Cell Lung Cancer: A Glimpse of Hope in Time of Crisis?

Clinical lung cancer, 2024-06

2024

Volltextzugriff (PDF)

Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy

Journal of thoracic oncology, 2021-06, Vol.16 (6), p.1030-1041

2021

Volltextzugriff (PDF)

Synthesis and preclinical evaluation of two osimertinib isotopologues labeled with carbon-11 as PET tracers targeting the tyrosine kinase domain of the epidermal growth factor receptor

Nuclear medicine and biology, 2023-05, Vol.120-121, p.108349, Article 108349

2023

Volltextzugriff (PDF)

Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non–Small-Cell Lung Cancer: A Clash of the Generations

Clinical lung cancer, 2020-05, Vol.21 (3), p.e216-e228

2020

Volltextzugriff (PDF)

Efficacy of osimertinib against EGFRvIII+ glioblastoma

Oncotarget, 2020-06, Vol.11 (22), p.2074-2082

2020

Volltextzugriff (PDF)

Sequential afatinib and osimertinib in patients with

Future oncology (London, England), 2020-12, Vol.16 (34), p.2799-2808

2020

Volltextzugriff (PDF)

Unfavorable response to capmatinib for MET exon14 skipping after first-line osimertinib in a patient with EGFR-mutated lung adenocarcinoma: A case report and literature review

Respiratory investigation, 2024-07, Vol.62 (4), p.677-680

2024

Volltextzugriff (PDF)

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

Annals of oncology, 2020-04, Vol.31 (4), p.507-516

2020

Volltextzugriff (PDF)

Metastatic Lung Tumors from Colorectal Cancer with EGFR Mutations that Responded to Osimertinib

Internal Medicine, 2022, pp.0002-22

2022

Volltextzugriff (PDF)

Safety and efficacy of osimertinib rechallenge or continuation after pneumonitis: A multicentre retrospective cohort study

European journal of cancer (1990), 2023-01, Vol.179, p.15-24

2023

Volltextzugriff (PDF)

Successful osimertinib rechallenge without concomitant corticosteroids after osimertinib-induced pneumonitis

Respiratory medicine case reports, 2024-01, Vol.49, p.102029, Article 102029

2024

Volltextzugriff (PDF)

Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis

Pharmacological research, 2023-02, Vol.188, p.106668-106668, Article 106668

2023

Volltextzugriff (PDF)

Successful Treatment with Ramucirumab Plus Erlotinib following Osimertinib-induced Interstitial Lung Disease: A Case Report

Internal Medicine, 2024, pp.3932-24

2024

Volltextzugriff (PDF)

Resistance mechanisms to osimertinib and emerging therapeutic strategies in nonsmall cell lung cancer

Current opinion in oncology, 2022-01, Vol.34 (1), p.54

2022

Volltextzugriff (PDF)

Case report: Durable response of ensartinib targeting EML4-ALK fusion in osimertinib-resistant non-small cell lung cancer

Frontiers in pharmacology, 2024-07, Vol.15, p.1359403

2024

Volltextzugriff (PDF)

Identification of potential inhibitors for drug-resistant EGFR mutations in non-small cell lung cancer using whole exome sequencing data

Frontiers in pharmacology, 2024-07, Vol.15, p.1428158

2024

Volltextzugriff (PDF)

A sulfonyl fluoride derivative inhibits EGFRL858R/T790M/C797S by covalent modification of the catalytic lysine

European journal of medicinal chemistry, 2021-12, Vol.225, p.113786-113786, Article 113786

2021

Volltextzugriff (PDF)

Exploring the structural activity relationship of the Osimertinib: A covalent inhibitor of double mutant EGFRL858R/T790M tyrosine kinase for the treatment of Non-Small Cell Lung Cancer (NSCLC)

Bioorganic & medicinal chemistry, 2024-07, Vol.109, p.117796, Article 117796

2024

Volltextzugriff (PDF)

Successful Treatment with Afatinib after Osimertinib-induced Interstitial Lung Disease in a Patient with EGFR-mutant Non-small-cell Lung Cancer: A Case Report

Internal Medicine, 2021, pp.5435-20

2021

Volltextzugriff (PDF)

Marginal Zone Lymphoma and Lung Adenocarcinoma with an EGFR Exon 19 E746-S752del Mutation in a Patient with IgG4-related Disease

Internal Medicine, 2021, pp.6470-20

2021

Volltextzugriff (PDF)

1 – 25 von 1.618

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.223)
Mit Volltextzugriff
(1.336)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

5 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Osimertinib
(1.531)
Science & Technology
(1.173)
Life Sciences & Biomedicine
(1.139)
Oncology
(799)
Mutation
(657)
Humans
(634)
Lung Cancer
(611)
Non-Small Cell Lung Cancer
(525)
Lung Neoplasms - Drug Therapy
(516)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(449)
Erbb Receptors - Genetics
(426)
Lung Neoplasms - Genetics
(407)
Carcinoma, Non-Small-Cell Lung - Genetics
(354)
Epidermal Growth Factor
(326)
Targeted Cancer Therapy
(325)
Patients
(282)
Protein Kinase Inhibitors - Therapeutic Use
(267)
Respiratory System
(265)
Egfr
(258)
Female
(254)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(49)
... seit 30 Tagen
(12)

Menü

Weitere Dienste

Einstellungen

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines

Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines

Inorganic sulfides prevent osimertinib-induced mitochondrial dysfunction in human iPS cell-derived cardiomyocytes

Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations

Strategies for enhancing non-small cell lung cancer treatment: Integrating Chinese herbal medicines with epidermal growth factor receptor-tyrosine kinase inhibitors therapy

Gefitinib Resensitization After a TKI-Free Interval in Osimertinib Resistant Non–Small-Cell Lung Cancer: A Glimpse of Hope in Time of Crisis?

Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy

Synthesis and preclinical evaluation of two osimertinib isotopologues labeled with carbon-11 as PET tracers targeting the tyrosine kinase domain of the epidermal growth factor receptor

Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non–Small-Cell Lung Cancer: A Clash of the Generations

Efficacy of osimertinib against EGFRvIII+ glioblastoma

Sequential afatinib and osimertinib in patients with

Unfavorable response to capmatinib for MET exon14 skipping after first-line osimertinib in a patient with EGFR-mutated lung adenocarcinoma: A case report and literature review

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

Metastatic Lung Tumors from Colorectal Cancer with EGFR Mutations that Responded to Osimertinib

Safety and efficacy of osimertinib rechallenge or continuation after pneumonitis: A multicentre retrospective cohort study

Successful osimertinib rechallenge without concomitant corticosteroids after osimertinib-induced pneumonitis

Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis

Successful Treatment with Ramucirumab Plus Erlotinib following Osimertinib-induced Interstitial Lung Disease: A Case Report

Resistance mechanisms to osimertinib and emerging therapeutic strategies in nonsmall cell lung cancer

Case report: Durable response of ensartinib targeting EML4-ALK fusion in osimertinib-resistant non-small cell lung cancer

Identification of potential inhibitors for drug-resistant EGFR mutations in non-small cell lung cancer using whole exome sequencing data

A sulfonyl fluoride derivative inhibits EGFRL858R/T790M/C797S by covalent modification of the catalytic lysine

Exploring the structural activity relationship of the Osimertinib: A covalent inhibitor of double mutant EGFRL858R/T790M tyrosine kinase for the treatment of Non-Small Cell Lung Cancer (NSCLC)

Successful Treatment with Afatinib after Osimertinib-induced Interstitial Lung Disease in a Patient with EGFR-mutant Non-small-cell Lung Cancer: A Case Report

Marginal Zone Lymphoma and Lung Adenocarcinoma with an EGFR Exon 19 E746-S752del Mutation in a Patient with IgG4-related Disease

Suchergebnisse filtern